Literature DB >> 18282654

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.

S Dvorakova1, E Vaclavikova, V Sykorova, J Vcelak, Z Novak, J Duskova, A Ryska, J Laco, J Cap, D Kodetova, R Kodet, L Krskova, P Vlcek, J Astl, D Vesely, B Bendlova.   

Abstract

The frequency and prognostic relevance of RET proto-oncogene somatic mutations in sporadic medullary thyroid carcinoma (MTC) remain controversial. In order to study somatic mutations in the RET proto-oncogene in sporadic MTCs found in the Czech population and to correlate these mutations with clinical and pathological characteristics, we investigated 48 truly sporadic MTCs by sequencing classical risk exons 10, 11, 13, 14, 15 and 16. From the 48 tumors studied, 23 (48%) had somatic mutation in the RET proto-oncogene in exons 10, 11, 15 or 16. The classical somatic mutation Met918Thr in exon 16 was only found in 13 tumors (27%). In five cases, multiple somatic mutations and deletions were detected. A statistically significant correlation between the presence of somatic mutation with more advanced pathological TNM stages was observed. Other clinical and pathological characteristics did not show any statistical significant association with the presence or absence of somatic mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18282654     DOI: 10.1016/j.mce.2007.12.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  33 in total

Review 1.  Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.

Authors:  Benedetta Fibbi; Pamela Pinzani; Francesca Salvianti; Matteo Rossi; Luisa Petrone; Maria Laura De Feo; Roberto Panconesi; Vania Vezzosi; Simonetta Bianchi; Gabriele Simontacchi; Monica Mangoni; Maurizio Pertici; Gianni Forti; Cinzia Pupilli
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

Review 2.  Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Authors:  Keith C Bible; Mabel Ryder
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

3.  Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.

Authors:  Christopher Griffith; Shengle Zhang; Sanjay Mukhopadhyay
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

4.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

5.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

Review 6.  Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.

Authors:  Carles Zafon; Juan J Díez; Juan C Galofré; David S Cooper
Journal:  Eur Thyroid J       Date:  2017-03-03

7.  Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.

Authors:  Thereasa A Rich; Karen L Reckamp; Young Kwang Chae; Robert C Doebele; Wade T Iams; Michael Oh; Victoria M Raymond; Richard B Lanman; Jonathan W Riess; Thomas E Stinchcombe; Vivek Subbiah; David R Trevarthen; Stephen Fairclough; Jennifer Yen; Oliver Gautschi
Journal:  Clin Cancer Res       Date:  2019-07-12       Impact factor: 12.531

8.  Diagnosis of medullary thyroid cancer.

Authors:  Stefania Marchisotta; Furio Pacini
Journal:  F1000 Med Rep       Date:  2009-03-17

9.  Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

Authors:  Michael W Ronellenfitsch; Patrick N Harter; Martina Kirchner; Christoph Heining; Barbara Hutter; Laura Gieldon; Jens Schittenhelm; Martin U Schuhmann; Marcos Tatagiba; Gerhard Marquardt; Marlies Wagner; Volker Endris; Christian H Brandts; Victor-Felix Mautner; Evelin Schröck; Wilko Weichert; Benedikt Brors; Andreas von Deimling; Michel Mittelbronn; Joachim P Steinbach; David E Reuss; Hanno Glimm; Albrecht Stenzinger; Stefan Fröhling
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 10.  Familial non-medullary thyroid carcinoma: an update.

Authors:  Vânia Nosé
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.